Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | IDH2 | P48735 | 10/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.48 |
| ▸ | GOT1 | P17174 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1391864 | 0.96 | LMNA (0.56) | MAPTIDH2TRPV1LMNAUSP2 | |
| SCHEMBL1391636 | 0.96 | MAPT (0.51) | MAPTIDH2TRPV1LMNAUSP2 | |
| SCHEMBL1391692 | 0.93 | MAPT (0.52) | MAPTIDH2TRPV1LMNAUSP2 | |
| SCHEMBL1391585 | 0.92 | APP (0.53) | MAPTIDH2TRPV1LMNAUSP2 | |
| SCHEMBL1391749 | 0.91 | MAPT (0.53) | MAPTIDH2TRPV1LMNAUSP2 | |
| SCHEMBL1391554 | 0.90 | MAPT (0.56) | MAPTIDH2LMNAUSP2SMN1; SMN2 | |
| SCHEMBL1392188 | 0.90 | MAPT (0.56) | MAPTIDH2LMNAUSP2SMN1; SMN2 | |
| SCHEMBL1391746 | 0.89 | IDH2 (0.55) | MAPTIDH2USP2SMN1; SMN2APP | |
| SCHEMBL1391924 | 0.89 | MAPT (0.51) | MAPTIDH2LMNAUSP2SMN1; SMN2 | |
| SCHEMBL1391734 | 0.88 | IDH2 (0.50) | MAPTIDH2TRPV1LMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2231624-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | Progenics Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009091388-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | HAVCR2, ZC3HAV1, MAVS | MAPT 3654/4885IDH2 1936/4885TRPV1 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.